Multivariate regression analysis to assess the influence of each pretreatment factor on BCVA change at 2 and 3 years after intravitreal bevacizumab treatment
| Factor | BCVA change at 2 years | BCVA change at 3 years | ||||||
| B | 95% CI | β | p Value | B | 95% CI | β | p Value | |
| Baseline BCVA (No of ETDRS letters) | −0.49 | −0.7 to −0.3 | −0.632 | <0.0001 | −0.49 | −0.8 to −0.2 | −0.572 | 0.001 |
| Age (years) | −0.32 | −0.6 to −0.06 | −0.338 | 0.019 | −0.39 | −0.7 to −0.1 | −0.417 | 0.01 |
| CNV location | 0.094 | 0.640 | 0.244 | 0.231 | ||||
| Axial length (mm) | −0.045 | 0.745 | −0.231 | 0.125 | ||||
| Baseline CNV area (mm2) | −0.022 | 0.883 | −0.135 | 0.405 | ||||
| Peripapillary atrophy area (mm2) | 0.027 | 0.861 | −0.223 | 0.192 | ||||
| Adjusted R2 | 0.452 | 0.418 | ||||||
β, standardised regression coefficient; adjusted R2, coefficient of multiple determination; B, non-standardised regression coefficient.
BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; ETDRS, Early Treatment Diabetic Retinopathy Study.